-
2023-506253-38-00
5
2020-11-09
Migraine
-
2024-512837-34-00
5
2020-10-14
Episodic and Chronic Migraine
-
2022-502480-38-00
5
2020-09-09
Non−small cell lung cancer (NSCLC)
-
2023-507846-96-00
5
2020-06-19
Type 2 Diabetes Mellitus
-
2023-508364-29-00
5
2019-11-22
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2022-502380-37-00
5
2019-08-02
Open-Angle Glaucoma
-
2023-504928-26-00
5
2019-07-19
Chronic Migraine
-
2022-501439-18-00
5
2019-06-26
NSCLC with squamous or nonsquamous histology
-
2023-509304-16-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2023-508365-33-00
5
2019-04-09
Hereditary Transthyretin Amyloidosis
-
2023-508655-39-00
7
2019-02-13
Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML)
-
2023-507330-24-00
9
2019-02-07
Chronic Graft Versus Host Disease (cGVHD)
-
2024-511553-22-00
5
2018-10-05
Moderately to Severely Active Crohn's Disease
-
2023-510426-33-00
5
2018-09-27
Moderately to Severely Active Crohn's Disease
-
2024-511533-35-00
4
2018-09-03
Mantle Cell Lymphoma
-
2023-509711-83-00
5
2017-10-27
Advanced or Metastatic Renal Cell Carcinoma
-
2024-511967-26-00
5
2016-11-21
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
-
2024-511235-10-00
5
2016-07-25
Generalized mantle cell Lymphoma
-
2024-517856-36-00
5
2015-03-09
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
-
2023-504761-23-00
5
2014-11-19
Advanced or metastatic renal cell carcinoma
-
2024-511639-83-00
9
2014-09-01
Anaplastic Large T-cell Lymphoma ALK negative
-
2023-507001-34-00
4
2010-04-29
Patients symptomatic with pulmonary hypertension associated with left
-
2022-500302-18-00
4
Epilepsy
-
2022-502268-18-00
5
Neurocognitive Disorders